{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:19:48Z","timestamp":1791443988686,"version":"4.3.3"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004685","name":"Universidad Autonoma de Nuevo Leon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004685","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.leukres.2023.107373","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T02:18:15Z","timestamp":1692670695000},"page":"107373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Low dose venetoclax plus itraconazole outpatient induction in newly diagnosed acute myeloid leukemia: A phase 2 study"],"prefix":"10.1016","volume":"133","author":[{"given":"Fernando","family":"De la Garza-Salazar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perla Roc\u00edo","family":"Colunga-Pedraza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"G\u00f3mez-Almaguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria Abigail","family":"Garc\u00eda-Z\u00e1rate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"G\u00f3mez-De Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.leukres.2023.107373_bib1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Eng. J. Med."},{"issue":"12","key":"10.1016\/j.leukres.2023.107373_bib2","first-page":"1","article-title":"to therapy for acute myeloid leukemia in the developing world: barriers and solutions","volume":"22","author":"Meillon","year":"2020","journal-title":"Curr. Oncol. Rep."},{"issue":"4","key":"10.1016\/j.leukres.2023.107373_bib3","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/bloodadvances.2019000707","article-title":"Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"4","author":"Mabrey","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2023.107373_bib4","article-title":"Orbital myeloid sarcoma treated with low-dose venetoclax and a potent cytochrome P450 inhibitor","author":"De la Garza","year":"2022","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.leukres.2023.107373_bib5","first-page":"1","article-title":"Cytochrome P450 inhibition to decrease dosage and costs of venetoclax and ibrutinib: a proof-of-concept case study","author":"De la Garza","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"0","key":"10.1016\/j.leukres.2023.107373_bib6","article-title":"Economic burden in US patients with newly diagnosed acute myeloid leukemia receiving intensive induction chemotherapy","author":"Huasa","year":"2022","journal-title":"Future Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2023.107373_bib7","first-page":"391","article-title":"The effect of cytochrome metabolism on drug response, interactions, and adverse effects","volume":"76","author":"Lynch","year":"2007","journal-title":"Am. Fam. Physician"},{"issue":"4","key":"10.1016\/j.leukres.2023.107373_bib8","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bcp.13175","article-title":"Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non- Hodgkin lymphoma","volume":"83","author":"Agarwal","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.leukres.2023.107373_bib9","unstructured":"Center for Drug Evaluation and Research. Table of substrates, inhibitors and inducers. U.S. Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/drug=interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and inducers. (Accessed 26 June 2022)."},{"issue":"1","key":"10.1016\/j.leukres.2023.107373_bib10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/16078454.2021.2024940","article-title":"Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America","volume":"27","author":"G\u00f3mez","year":"2022","journal-title":"Hematology"},{"issue":"9","key":"10.1016\/j.leukres.2023.107373_bib11","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/leu.2012.122","article-title":"EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols","volume":"26","author":"Kalina","year":"2012","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2023.107373_bib12","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/j.clml.2019.12.015","article-title":"Acute myeloid Leukemia in Mexico: the specific challenges of a developing country. Results from a multicenter national registry","volume":"20","author":"Demichelis","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2023.107373_bib13","unstructured":"Savarese D.M. Common terminology criteria for adverse events. https:\/\/www.uptodate.com\/contents\/common-terminology-criteria-for-adverse-events. Accessed 20 December 2022)."},{"issue":"3","key":"10.1016\/j.leukres.2023.107373_bib14","first-page":"259","article-title":"Outpatient haploidentical stem cell transplantation using post-transplant cyclophosphamide is safe and feasible","volume":"27","author":"Colunga","year":"2021","journal-title":"Transpl. Cell Ther."},{"issue":"12","key":"10.1016\/j.leukres.2023.107373_bib15","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1038\/s41375-020-0806-0","article-title":"Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"34","author":"Herold","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107373_bib16","doi-asserted-by":"crossref","unstructured":"A. Kassambara, M. Kosinski, P. Biecek, S. Fabian. Package \u2018survminer\u2019. Drawing Survival Curves using \u2018ggplot2\u2032(R package version 03 1). https:\/\/cran.microsoft.com\/snapshot\/2017\u201304-21\/web\/packages\/survminer\/survminer.pdf. (Accessed 19 December 2022).","DOI":"10.32614\/CRAN.package.survminer"},{"issue":"11","key":"10.1016\/j.leukres.2023.107373_bib17","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/oncolo\/oyac135","article-title":"Venetoclax and hypomethylating agents as first-line treatment in newly diagnosed patients with AML in a predominately community setting in the US","volume":"27","author":"Kachbaoi","year":"2022","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.leukres.2023.107373_bib18","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ajh.24767","article-title":"Early mortality and overall survival of acute myeloid leukemia based on facility type","volume":"92","author":"Bhatt","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.leukres.2023.107373_bib19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clml.2018.02.002","article-title":"Outcomes of adolescents and young adults with acute myeloid leukemia treated in a single Latin American center","volume":"18","author":"Jaime","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.leukres.2023.107373_bib20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bjh.13406","article-title":"Acute myeloid leukaemia: challenges and real world data from India","volume":"170","author":"Philip","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.leukres.2023.107373_bib21","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.clml.2021.07.008","article-title":"The real-life efficacy of fixed-dose hypomethylating agents in older patients with acute myeloid leukemia: a 10-Year experience","volume":"21","author":"Rungjirajittranon","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"7","key":"10.1016\/j.leukres.2023.107373_bib22","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+ 3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol."},{"issue":"4","key":"10.1016\/j.leukres.2023.107373_bib23","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41375-021-01425-9","article-title":"Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries","volume":"36","author":"R\u00e9cher","year":"2022","journal-title":"Leukemia"},{"issue":"xx","key":"10.1016\/j.leukres.2023.107373_bib24","first-page":"1","article-title":"Outcomes and survival predictors of Latin American older adults with acute myeloid leukemia: data from a single center","volume":"xxx","author":"Jaime","year":"2022","journal-title":"Hematol. Transfus. Cell Ther."},{"issue":"11","key":"10.1016\/j.leukres.2023.107373_bib25","doi-asserted-by":"crossref","first-page":"E422","DOI":"10.1002\/ajh.26707","article-title":"Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study","volume":"97","author":"Jonas","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2023.107373_bib26","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/jcph.858","article-title":"Quantitative prediction of the effect of CYP3A inhibitors and inducers on venetoclax pharmacokinetics using a physiologically based pharmacokinetic model","volume":"57","author":"Freise","year":"2017","journal-title":"J. Clin. Pharm."},{"issue":"12","key":"10.1016\/j.leukres.2023.107373_bib27","first-page":"1","article-title":"Utility of therapeutic drug monitoring of venetoclax in acute myeloid leukemia","volume":"39","author":"Kobayashi","year":"2022","journal-title":"Oncology"},{"issue":"11","key":"10.1016\/j.leukres.2023.107373_bib28","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.3390\/ijms23116260","article-title":"Venetoclax induces cardiotoxicity through modulation of oxidative-stress-mediated cardiac inflammation and apoptosis via NF-KB and BCL-2 pathway","volume":"23","author":"AlAsmari","year":"2022","journal-title":"Int J. Mol. Sci."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623006380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623006380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:04:37Z","timestamp":1758935077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212623006380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":28,"alternative-id":["S0145212623006380"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107373","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low dose venetoclax plus itraconazole outpatient induction in newly diagnosed acute myeloid leukemia: A phase 2 study","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107373","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107373"}}